Loading clinical trials...
Loading clinical trials...
Explorations of Cell-free DNA Multi-omics Technology in Detection of Minimal Residual Disease and Disease Prognosis After Surgery in Early Pancreatic Ductal Adenocarcinoma: A Single-center, Prospective, Observational Case Study
Conditions
Interventions
Blood collection and Pancreatic ductal adenocarcinoma minimal residual disease detection test
Locations
1
China
Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University; 270 Dong An Road, Shanghai 200032, China
Shanghai, China
Start Date
December 1, 2023
Primary Completion Date
September 30, 2025
Completion Date
November 30, 2025
Last Updated
November 30, 2023
NCT04657068
NCT06445062
NCT04900818
NCT07432633
NCT06005493
NCT04851119
Lead Sponsor
Fudan University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions